Endothelin receptor blockade as a therapeutic strategy in ameliorating postischemic damage to the liver microcirculation
- PMID: 11078418
- DOI: 10.1097/00005344-200036051-00102
Endothelin receptor blockade as a therapeutic strategy in ameliorating postischemic damage to the liver microcirculation
Abstract
Ischemia leads to profound endothelin- (ET) related constriction of hepatic microvessels, causing disturbances in blood and oxygen supply. The aim of the study was to modulate hepatic microvascular diameters by blocking ET receptors to find the optimal therapeutic vessel width for reduction of ischemia-reperfusion injury. In an in vivo model (84 female Wistar rats, 250-300 g) with portal decompression by means of a splenocaval shunt, normothermic hepatic ischemia was induced for 30 min by crossclamping of the hepatoduodenal ligament. The ET receptor antagonist (ERA) bosentan was administered before induction of ischemia in different dosages [0.1, 1.0 and 10.0 mg/kg body weight (BW) i.v. and 10 mg/kg BW intraportally (i.p.)]. The effect on microcirculation was assessed by in vivo microscopy and influence on hepatocellular function by measurement of aspartate aminotransferase (AST) levels. Sinusoidal diameters were reduced as a result of ischemia to 76.3 +/- 7.4% compared with values received from sham-operated animals. After application of 0.1 mg/kg of bosentan, sinusoids remained constricted (89.7 +/- 9.9%, AST 255.0 +/- 12.8 U/l). Blocking ET receptors with 1 mg/kg bosentan avoided sinusoidal constriction (99.0 +/- 8.8%, p < 0.05) and led to the most effective reduction of AST level peak after 6 h of reperfusion (244.0 +/- 34.2 U/l vs 422.9 +/- 163.3 U/l in untreated ischemia). Bosentan (10 mg/kg i.v.) caused an increase in sinusoidal diameter to 109.1 +/- 6.4% (AST 311.7 +/- 33.6 U/l) and 10 mg/kg i.p. to 136.8 +/- 19.3% and even increase AST levels (618.90 +/- 209.32 U/l). After intravenous application of 1 and 10 mg/kg BW bosentan the perfusion rate was significantly increased and sticking of leukocytes in sinusoids and venules reduced (p < 0.05). In our model, diameters of sinusoids and postsinusoidal venules could be regulated gradually. We conclude that the avoidance of constriction, but not an excessive vasodilation leads to increased perfusion rate and hence improved hepatocellular function.
Similar articles
-
Pharmacological regulation of postischemic sinusoidal diameters in rats--a new approach for reducing hepatic ischemia/reperfusion injury.Clin Hemorheol Microcirc. 2001;24(4):233-46. Clin Hemorheol Microcirc. 2001. PMID: 11564912
-
Involvement of endothelin/nitric oxide balance in hepatic ischemia/reperfusion injury.Langenbecks Arch Surg. 1999 Feb;384(1):65-70. doi: 10.1007/s004230050176. Langenbecks Arch Surg. 1999. PMID: 10367633
-
Controlled vasoregulation of postischemic liver microcirculation--a therapeutic approach.J Invest Surg. 2000 Sep-Oct;13(5):273-8. doi: 10.1080/08941930050206292. J Invest Surg. 2000. PMID: 11071563
-
Effect of the endothelin receptor antagonist bosentan on postischemic liver microcirculation.Zentralbl Chir. 1996;121(9):788-93. Zentralbl Chir. 1996. PMID: 8921579
-
Hepatic circulation: potential for therapeutic intervention.Pharmacol Ther. 1990;47(2):281-328. doi: 10.1016/0163-7258(90)90091-f. Pharmacol Ther. 1990. PMID: 2203072 Free PMC article. Review.
Cited by
-
How Donor and Surgical Factors Affect the Viability and Functionality of Human Hepatocytes Isolated From Liver Resections.Front Med (Lausanne). 2022 May 11;9:875147. doi: 10.3389/fmed.2022.875147. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35646956 Free PMC article.
-
Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models.Liver Transpl. 2008 Dec;14(12):1737-44. doi: 10.1002/lt.21621. Liver Transpl. 2008. PMID: 19025917 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources